From: The correlation between HTA recommendations and reimbursement status of orphan drugs in Europe
Countrya | Assessed orphan drugs (out of 101) | Assessed orphan drugs | Reimbursed orphan drugs | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Positive | Conditional | Negative | Assessed orphan drugs | Not assessed orphan drugs | |||||||||||||||
Total number | Out of 101 | Out of assessed drugs | Positive | Conditional | Negative | ||||||||||||||
England | 20 % | 20 | 60 % | 12 | 5 % | 1 | 35 % | 7 | 13 | 13 % | 65 % | 25 % | 3 | 0 % | 0 | 14 % | 1 | 11 % | 9 |
Germany | 25 % | 25 | 100 % | 25 | 0 % | 0 | 0 % | 0 | 20 | 20 % | 80 % | 76 % | 19 | 0 % | 0 | 0 % | 0 | 1 % | 1 |
Poland | 36 % | 36 | 19 % | 7 | 36 % | 13 | 44 % | 16 | 23 | 23 % | 64 % | 71 % | 5 | 69 % | 9 | 31 % | 5 | 6 % | 4 |
Netherlands | 38 % | 38 | 13 % | 5 | 74 % | 28 | 13 % | 5 | 30 | 30 % | 79 % | 20 % | 1 | 75 % | 21 | 40 % | 2 | 10 % | 6 |
Sweden | 43 % | 43 | 95 % | 41 | 0 % | 0 | 5 % | 2 | 41 | 41 % | 95 % | 100 % | 41 | 0 % | 0 | 0 % | 0 | 0 % | 0 |
Scotland | 60 % | 61 | 51 % | 31 | 2 % | 1 | 48 % | 29 | 11 | 11 % | 18 % | 19 % | 6 | 0 % | 0 | 10 % | 3 | 5 % | 2 |
Wales | 67 % | 68 | 28 % | 19 | 9 % | 6 | 63 % | 43 | 13 | 13 % | 19 % | 32 % | 6 | 0 % | 0 | 12 % | 5 | 6 % | 2 |
France | 74 % | 75 | 85 % | 64 | 9 % | 7 | 5 % | 4 | 20 | 20 % | 27 % | 30 % | 19 | 0 % | 0 | 25 % | 1 | 0 % | 0 |